Find information on how we’re keeping you safe from COVID-19 here

To top

Areas of Expertise

Professor Howard treats various conditions including the following:

  • Unexplained breathlessness and exercise intolerance
  • Pulmonary embolism
  • Pulmonary hypertension

Some of the treatments and procedures he offers are:

Personal Biography

Professor Luke Howard completed his undergraduate training in Physiological Sciences at the University of Oxford, which he followed directly with his research doctorate, also at Oxford, in Altitude Physiology. He moved to the University of Cambridge to complete his clinical studies. He acquired his general medical training in London at the Royal Brompton Hospital and Guys and St Thomas’ Hospital and then undertook specialist training in Cambridge and Papworth before moving back to London to take up his current consultant position.

Professor Howard was appointed Consultant Pulmonologist to the National Pulmonary Hypertension Service at Hammersmith Hospital, Imperial College Healthcare NHS Trust, London in 2006. He also holds an honorary Clinical Senior Lecturer post at the National Heart and Lung Institute, Imperial College London. He runs the Exercise Physiology Service, based at Hammersmith Hospital.

He has an active research programme in Pulmonary Hypertension and Exercise Physiology, as well as sitting on national and international committees and guideline groups for pulmonary hypertension, pulmonary embolism, oxygen therapy and air travel. He is regarded as an international expert, lecturing around the world in his areas of interest.

Research and Publications

Main research interests:

  • Early phase clinical studies in pulmonary hypertension examining new targets with novel clinical end-points.
  • Use of wearables in telemedicine and clinical trials

Notable Publications

Cannon, J. E., L. Su, D. G. Kiely, K. Page, M. Toshner, E. Swietlik, C. Treacy, A. Ponnaberanam, R. Condliffe, K. Sheares, D. Taboada, J. Dunning, S. Tsui, C. Ng, D. Gopalan, N. Screaton, C. Elliot, S. Gibbs, L. Howard, P. Corris, J. Lordan, M. Johnson, A. Peacock, R. MacKenzie-Ross, B. Schreiber, G. Coghlan, K. Dimopoulos, S. J. Wort, S. Gaine, S. Moledina, D. P. Jenkins and J. Pepke-Zaba (2016). “Dynamic Risk Stratification of Patient Long-Term Outcome After Pulmonary Endarterectomy: Results From the United Kingdom National Cohort.” Circulation 133(18): 1761-1771.  https://www.ahajournals.org/doi/full/10.1161/CIRCULATIONAHA.115.019470

Charalampopoulos, A., J. S. Gibbs, R. J. Davies, W. Gin-Sing, K. Murphy, K. K. Sheares, J. Pepke-Zaba, D. P. Jenkins and L. S. Howard (2016). “Exercise physiological responses to drug treatments in chronic thromboembolic pulmonary hypertension.” J Appl Physiol (1985) 121(3): 623-628.  https://journals.physiology.org/doi/pdf/10.1152/japplphysiol.00087.2016

Ghofrani, H. A., G. Simonneau, A. M. D’Armini, P. Fedullo, L. S. Howard, X. Jais, D. P. Jenkins, Z. C. Jing, M. M. Madani, N. Martin, E. Mayer, K. Papadakis, D. Richard, N. H. Kim and M. s. investigators (2017). “Macitentan for the treatment of inoperable chronic thromboembolic pulmonary hypertension (MERIT-1): results from the multicentre, phase 2, randomised, double-blind, placebo-controlled study.” Lancet Respir Med 5(10): 785-794.  https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(17)30305-3/fulltext

Howard, L., S. Barden, R. Condliffe, V. Connolly, C. W. H. Davies, J. Donaldson, B. Everett, C. Free, D. Horner, L. Hunter, J. Kaler, C. Nelson-Piercy, O. D. E, R. Patel, W. Preston, K. Sheares and T. Campbell (2018). “British Thoracic Society Guideline for the initial outpatient management of pulmonary embolism (PE).” Thorax 73(Suppl 2): ii1-ii29.  https://thorax.bmj.com/content/73/Suppl_2/ii1

Kovacs, G., P. Herve, J. A. Barbera, A. Chaouat, D. Chemla, R. Condliffe, G. Garcia, E. Grunig, L. Howard, M. Humbert, E. Lau, P. Laveneziana, G. D. Lewis, R. Naeije, A. Peacock, S. Rosenkranz, R. Saggar, S. Ulrich, D. Vizza, A. Vonk Noordegraaf and H. Olschewski (2017). “An official European Respiratory Society statement: pulmonary haemodynamics during exercise.” Eur Respir J 50(5).  https://erj.ersjournals.com/content/50/5/1700578

McGoon, M. D., P. Ferrari, I. Armstrong, M. Denis, L. S. Howard, G. Lowe, S. Mehta, N. Murakami and B. A. Wong (2019). “The importance of patient perspectives in pulmonary hypertension.” Eur Respir J 53(1).   https://erj.ersjournals.com/content/53/1/1801919.abstract

Rosenkranz, S., L. S. Howard, M. Gomberg-Maitland and M. M. Hoeper (2020). “Systemic Consequences of Pulmonary Hypertension and Right-Sided Heart Failure.” Circulation 141(8): 678-693.   https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.116.022362

Rothman, A. M. K., J. L. Vachiery, L. S. Howard, G. W. Mikhail, I. M. Lang, M. Jonas, D. G. Kiely, D. Shav, O. Shabtay, A. Avriel, G. D. Lewis, E. B. Rosenzweig, A. J. Kirtane, N. H. Kim, E. Mahmud, V. V. McLaughlain, S. Chetcuti, M. B. Leon, O. Ben-Yehuda and L. J. Rubin (2020). “Intravascular Ultrasound Pulmonary Artery Denervation to Treat Pulmonary Arterial Hypertension (TROPHY1): Multicenter, Early Feasibility Study.” JACC Cardiovasc Interv 13(8): 989-999.  https://interventions.onlinejacc.org/content/13/8/989

Su, J., C. Manisty, K. H. Parker, U. Simonsen, J. E. Nielsen-Kudsk, S. Mellemkjaer, S. Connolly, P. B. Lim, Z. I. Whinnett, I. S. Malik, G. Watson, J. E. Davies, S. Gibbs, A. D. Hughes and L. Howard (2017). “Wave Intensity Analysis Provides Novel Insights Into Pulmonary Arterial Hypertension and Chronic Thromboembolic Pulmonary Hypertension.” J Am Heart Assoc 6(11).  https://pubmed.ncbi.nlm.nih.gov/29089339/

Zhai, Z., K. Murphy, H. Tighe, C. Wang, M. R. Wilkins, J. S. Gibbs and L. S. Howard (2011). “Differences in ventilatory inefficiency between pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension.” Chest 140(5): 1284-1291.  https://doi.org/10.1378/chest.10-335

  • Why did you choose to become a part of OneWelbeck?

    This was a great opportunity to come in to a collaborative environment from the outset and help to fashion the sort of services that work for both patients and physicians.

  • What are the moments which stand out most in your career so far?

    There are rarely specific moments, although certain individual patients always stick in one’s memory. Occasions when you have taken a different turn with a diagnostic or treatment pathway that has not been thought of or explored, but has been life changing for a patient. These strategies often require significant effort, but the result brings not only benefit for an individual, but can may pave the way for a new understanding of a condition or how certain drugs may work. More often, stand out moments happen when you look back at something you have helped to build over months to years and with great satisfaction you see the benefit it has given to many. Finally, like many being central to the acute COVID response, managing patients on the high dependency unit and then following up survivors will never be far from my most memorable experiences in my career.

  • What keeps you busy in your personal life?

    Family, rowing and cycling.